Overall verdict
Neutral
4.9/10
1-year performance
—
Score breakdown
Strongest: Financial strength 10.0/10. Weakest: Shareholder return 0.0/10.
Jiangxi Institute of Biological Products Inc. manufactures and exports biological products including Tetanus Antitoxin and Veterinary Medicine. The company offers Antitoxin Formulations, Active Pharmaceutical Ingredients, Equine Byproducts, essential oils, and plant extracts. It serves businesses in China and international markets. The company was founded in 1969 and is based in Ji'an, China. Jiangxi Institute of Biological Products Inc. is a subsidiary of Shenzhen Qianhai Tianzheng Biotechnology Co., Ltd.
Sector
Health Care
Industry
Biotechnology
Primary listing
Hkex
China
CEO
Xiaodong Yao
Founded
1969
Employees
327
Revenue / employee
780 751 HKD
Next earnings
December 1, 2026 (estimated)
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
—
52-week low
—
1-year performance
—
Year-to-date performance
—
Position in the 52-week range
—
Range: 6.01 HKD - 7.34 HKD (comparables only)
Gross margin 76.1%, net margin 33.0%, ROIC 17.0%, ROE 19.0%.
Net margin
33.02%
Exceptional
Sector -223.82%|S&P 13.15%
Gross margin
76.11%
Exceptional
Return on equity (ROE)
19.03%
Fair
Sector -58.80%|S&P 16.61%
Return on invested capital (ROIC)
16.99%
Fair
Free cash flow margin (FCF)
8.83%
Fair
Profit-to-cash conversion (FCF conversion)
0.27x
Low
Growth
3.5/10Revenue down 16.5% over 1 year.
Revenue (trailing 12 months)
219M HKD
Revenue growth (1y)
-16.50%
Declining
Revenue growth (3y)
54.66%
Strong
EPS growth (1y)
26.19%
Solid
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
4.8/10P/E 26.9x, EV/EBITDA 14.3x.
P/E (TTM)
26.9x
Very expensive
Sector 11.4x|S&P 24.1x
Forward P/E (adjusted)
—
EV / EBITDA
14.3x
Fair
Sector 14.4x|S&P 15.2x
PEG
—
Sector -0.03|S&P 0.90
Fair value (reverse DCF)
6.68 HKD
Fairly priced
Market cap
2.2Md HKD
Financial strength
10.0/10Cash covers 40545.6% of the debt, net debt/EBITDA -0.7x.
Net debt / EBITDA
-0.7x
Net cash
Gearing (net debt / equity)
-48.28%
Net cash
Cash
468M HKD
Cash / market cap
20.90%
Very solid
Cash / total debt
40545.63%
Net cash
Interest coverage
2971.9x
Very solid
Net debt
-467M HKD
Equity
966M HKD
Closed daily candles, 4 months
Last close on October 21, 2026: 7.26 HKD
- MM2010.22
- MM5013.70
- RSI 1430.6
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
50-day average slope, 1 month
+0.51%
Bullish RSI divergence
No
20-day volatility
7.19 % per day
Volatility change
-30.20%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | — | — | 302 (1) | — | 139 (1) |
| 2027 | — | — | 462 (1) | — | 194 (1) |
Amounts in millions of CNY, EPS in CNY per share. In brackets, the number of analysts. Consensus as of August 19, 2026.
Same sub-industry: 781 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AGEN | 5.6 | 4.9 | 289M USD | 2.4x | 69.3 % | 34.4 % | -11.7 % | 6.7x | -34.1 % | 44.8 % | ||
| 2 | SRZN | 5.5 | 4.3 | 298M USD | Not meaningful (loss) | -3042.9 % | 408.6 % | — | 2.2x | -11.8 % | 87.6 % | ||
| 3 | 6915 | 4.9 | 4.9 | 285M USD | 26.9x | 33.0 % | -16.5 % | 17.0 % | -0.7x | 1.0 % | — | ||
| 4 | PRLD | 4.7 | 3.5 | 291M USD | Not meaningful (loss) | -269.7 % | 73.4 % | -50.5 % | 2.0x | -11.4 % | 182.9 % | ||
| 5 | BNTC | 4.4 | N/A | 297M USD | Not meaningful (loss) | — | — | -33.1 % | 3.5x | -5.9 % | -46.2 % | ||
| 6 | NWBO | 3.5 | 4.0 | 281M USD | Not meaningful (loss) | -1736.4 % | 535.4 % | 275.6 % | -1.3x | -17.7 % | -25.0 % | ||
| 7 | IPSC | 3.4 | 1.5 | 292M USD | Not meaningful (loss) | -100.6 % | 1556.8 % | -41.9 % | 0.9x | -30.2 % | 182.2 % | ||
| 8 | XFOR | 3.2 | 3.0 | 298M USD | Not meaningful (loss) | -568.8 % | 346.3 % | -57.6 % | 1.5x | — | -4.4 % | ||
| 9 | A376900 | 2.7 | 3.0 | 279M USD | Not meaningful (loss) | -38.7 % | 36.6 % | -161.2 % | -7.1x | -6.0 % | -46.6 % |
